Gamma-Glutamylcysteine.

Gamma-glutamylcysteine is the direct substrate for glutathione synthetase, and glycine is the co-substrate. Supplying the dipeptide without adequate glycine leaves the final step short of a partner. Glycine availability declines with age in some measures, which is one reason the pairing gets attention. The stoichiometry is one to one at that step.

Gamma-glutamylcysteine is the immediate precursor of glutathione and bypasses the rate-limiting first step of its synthesis. That first step, catalysed by glutamate-cysteine ligase, is feedback-inhibited by glutathione itself, which caps how far cysteine supplementation can push output. Delivering the dipeptide sidesteps that brake, which is the mechanistic argument for the ingredient. Supplying both the precursor and the product together is redundant at the same step rather than complementary.

Cysteine plus glutamate become gamma-glutamylcysteine under glutamate-cysteine ligase. Providing the dipeptide directly means that step has already happened, so the two ingredients are alternative entry points to the same pathway rather than additive ones. Cysteine entry is subject to the glutathione feedback brake. The dipeptide is not. Combining them mainly raises cost.

Both ingredients aim at the same endpoint by different entry points. NAC supplies cysteine into a step that glutathione itself throttles, while gamma-glutamylcysteine enters downstream of that throttle. Stacking them does not produce two independent effects, and anyone choosing between the two is choosing where on the pathway to enter, not whether to. Cost and tolerability, not potency, are the practical separators.

Glutamate supplies the gamma-glutamyl half of the dipeptide, and glutamine is the main circulating reservoir that feeds the glutamate pool. This matters for endogenous production of gamma-glutamylcysteine, not for a supplemented dose that already contains the glutamyl residue. Glutamate is rarely limiting in a normal diet.

Making more glutathione does not help much if the enzymes that use it are short of selenium. Glutathione peroxidases carry selenocysteine at the catalytic centre and cannot function without adequate selenium status. This is a floor requirement rather than a dose-response lever, and selenium above sufficiency is not a way to get more out of the pathway. Selenium also has a narrow window between adequate and excessive.

Glutathione does its work by being oxidised and then recycled back. That recycling runs through glutathione reductase, which needs FAD derived from riboflavin. Riboflavin status is measured clinically using exactly this enzyme's activation coefficient, which is how tightly the two are linked. Without adequate riboflavin the pool sits oxidised regardless of how much was synthesised.

Recycling oxidised glutathione consumes NADPH, largely supplied by the pentose phosphate pathway. Niacin status underpins the NADP pool that carries those electrons. This is background metabolic infrastructure rather than a targeted pairing, and it is not a reason to add niacin on top of a normal intake.

Lipoic acid in its reduced form can hand electrons to oxidised glutathione, which spares the enzymatic recycling route. The network also includes ascorbate and tocopherol, each capable of regenerating the next. This is established redox chemistry measured mostly in cells and in animals, and whether co-supplementation changes anything a person would notice has not been shown.

Glutathione can reduce the ascorbyl radical back to ascorbate, and ascorbate can spare glutathione consumption in the other direction. The two pools rise and fall together in depletion studies. This is network chemistry, not a claim that either one delivers a specific benefit when added to the other.

Cysteine can be made from homocysteine through the transsulfuration pathway, and both enzymes in that route need pyridoxal 5-phosphate. Inadequate B6 constrains endogenous cysteine supply and therefore the first synthesis step. This matters for how much gamma-glutamylcysteine the body makes on its own, not for a supplemented dose. The relevant study measured amino acid concentrations, which are markers rather than outcomes.

Homocysteine sits at a branch point, either remethylated back to methionine or committed down transsulfuration to cysteine. Folate status shifts the balance between those two exits. That makes folate a modulator of endogenous cysteine supply rather than a partner that adds to a supplemented dipeptide.

The liver holds the largest glutathione pool in the body and is where most glutathione-support formulations aim. Silymarin appears with glutathione precursors as a matter of product convention. No trial has tested the combination against either component. This is formulation practice, not a demonstrated pairing.

All sulfur entering the cysteine pool from the diet arrives as methionine or cysteine. Methionine passes through homocysteine and cystathionine to reach cysteine. This is the upstream supply line for endogenous synthesis, several steps before gamma-glutamylcysteine appears, and it is not usually limiting on an adequate protein intake.